This massive acquisition just made Amgen even bigger, and the market liked the news.
The following video is from Monday's Investor Beat, in which host Alison Southwick and Motley Fool analysts Matt Koppenheffer and Matt Argersinger dissect the hardest-hitting investing stories of the day.
Biotech giant Amgen (AMGN -0.19%) announced today that it's acquiring Onyx Pharmaceuticals (NASDAQ: ONXX) for $10.4 billion. In our lead story on Investor Beat, our two Matts discuss the acquisition and look at whether M&A in general is good news for investors.
Alison Southwick, Matt Koppenheffer, Matthew Argersinger, and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
